(c) 2024 PillSync.com

Oseltamivir 30 MG Oral Capsule

1 INDICATIONS AND USAGE Oseltamivir phosphate capsules are an influenza neuraminidase inhibitor (NAI) indicated for: Treatment of acute, uncomplicated influenza A and B in patients 2 weeks of age and older who have been symptomatic for no more than 48 hours. ( 1.1 ) Prophylaxis of influenza A and B in patients 1 year and older. ( 1.2 ) Limitations of Use: Not a substitute for annual influenza vaccination. ( 1.3 ) Consider available information on influenza drug susceptibility patterns and treatment effects when deciding whether to use. ( 1.3 ) Not recommended for patients with end-stage renal disease not undergoing dialysis. ( 1.3 ) 1.1 Treatment of Influenza Oseltamivir phosphate capsules are indicated for the treatment of acute, uncomplicated illness due to influenza A and B infection in patients 2 weeks of age and older who have been symptomatic for no more than 48 hours. 1.2 Prophylaxis of Influenza Oseltamivir phosphate capsules are indicated for the prophylaxis of influenza A and B in patients 1 year and older. 1.3 Limitations of Use Oseltamivir phosphate capsules are not a substitute for early influenza vaccination on an annual basis as recommended by the Centers for Disease Control and Prevention Advisory Committee on Immunization Practices. Influenza viruses change over time. Emergence of resistance substitutions could decrease drug effectiveness. Other factors (for example, changes in viral virulence) might also diminish clinical benefit of antiviral drugs. Prescribers should consider available information on influenza drug susceptibility patterns and treatment effects when deciding whether to use oseltamivir phosphate capsules [see Microbiology ( 12.4 )]. Oseltamivir phosphate capsules are not recommended for patients with end-stage renal disease not undergoing dialysis [see Dosage and Administration ( 2.4 ) and Use in Specific Populations ( 8.6 )] .

Alvogen Inc.


4 years ago CAPSULE YELLOW NAT 30mg Oseltamivir 30 MG Oral Capsule

CAPSULE YELLOW NAT 30mg

16 HOW SUPPLIED/STORAGE AND HANDLING

OSELTAMIVIR PHOSPHATE capsules, USP 30-mg capsules (39.40 mg of

OSELTAMIVIR PHOSPHATE is equivalent to 30 mg of oseltamivir (free base)): white to off-white powder filled in Size “4” capsule with yellow color cap imprinted with “30 mg” with blue color ink and yellow color body imprinted with “NAT” with blue color ink.

OSELTAMIVIR PHOSPHATE capsules, USP 30 mg, Blister pack of 10 Unit-of-Use – NDC 47781-468-13 45-mg capsules (59.10 mg of

OSELTAMIVIR PHOSPHATE is equivalent to 45 mg of oseltamivir (free base)): white to off-white powder filled in Size “4” capsule with grey color cap imprinted with “45 mg” with blue color ink and grey color body imprinted with “NAT” with blue color ink.

OSELTAMIVIR PHOSPHATE capsules, USP 45 mg, Blister pack of 10 Unit-of-Use – NDC 47781-469-13 75-mg capsules (98.50 mg of

OSELTAMIVIR PHOSPHATE is equivalent to 75 mg of oseltamivir (free base)): white to off-white powder filled in size "2" capsules with yellow color cap imprinted with "75 mg" with blue color ink and grey color body imprinted with "NAT" with blue color ink.

OSELTAMIVIR PHOSPHATE capsules, USP 75 mg, Blister pack of 10 Unit-of-Use – NDC 47781-470-13 Storage Store the capsules at 25ºC (77ºF); excursions permitted to 15º to 30ºC (59º to 86ºF) [See USP Controlled Room Temperature].


More pills like CAPSULE NAT 30mg












DISCLAIMER:

"This tool does not provide medical advice, and is for informational and educational purposes only, and is not a substitute for professional medical advice, treatment or diagnosis. Call your doctor to receive medical advice. If you think you may have a medical emergency, please dial 911."

"Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service."

"This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product."

PillSync may earn a commission via links on our site